samedan logo
 
 
spacer
home > pmps > winter 2002 > formulation integrated device systems for novel enhanced performance products
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Formulation Integrated Device Systems for Novel Enhanced Performance Products

The aim of developing formulation integrated device systems (FIDS) is to achieve enhanced performance from drugs, using technology that is aimed at solving specific biopharmaceutical, therapeutic, clinical or production problems. These patent-protected high performance systems are designed to provide better treatment outcomes and greater satisfaction for patients, whilst enabling new product development applications and enhanced Ôlife cycle managementÕ opportunities for pharmaceutical companies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor John N Staniforth, Chief Scientific Officer at Vectura Ltd
Professor John N Staniforth PhD MRPharmS FZS CChem FRSC Churchill Fellow, is Chief Scientific Officer of Vectura, a pharmaceutical company specialising in novel pulmonary, oral and dermal technology and new product developments, based in the UK.

John has authored over 200 scientific publications in the area of pharmaceutical technology and is an Honorary Professor of the University of Bath. He is a Non-Executive Director of Penwest Pharmaceuticals Co Inc, New York, and a Founding Director of the drug delivery company, Phoqus Pharmaceuticals Ltd, UK.

spacer
Professor John N Staniforth
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials

Reify Health today announced a $220 million Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement